

# **Comparison Between Farnisoid X Receptors (FXR) Level in Gastric Tissue of Patients With Gastritis versus Patients with Portal Hypertension**

*Thesis*

*Submitted For Partial Fulfillment of MSc Degree In  
Internal Medicine*

*Presented by*

**Helmy Adel Abd El Khalik El Sayed Aziza**

*M.B.B.Ch*

*Misr University For Science And Technology*

*Supervisors*

**Prof.Dr.Khaled Mohamed Hussien Abd El Wahab**

*Professor of Internal Medicine*

*Faculty of Medicine, Ain Shams University*

**Prof. Dr/ Amir Helmy Samy**

*Professor of Internal Medicine*

*Faculty of Medicine, Ain Shams University*

**Dr/Sarah Abdel Kader El Nakeep**

*Lecturer of Internal Medicine*

*Faculty of Medicine, Ain Shams University*

**Dr. Mohammed Ali Awaden**

*Lecturer of Internal Medicine*

*Misr University for Science and Technology*

*Faculty of Medicine  
Ain Shams University*

**2018**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا أنك لا تعلم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Khaled Abd El Wahab**, Professor of Internal Medicine Faculty of Medicine, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr/Amir Helmy Samy**, Professor of Internal Medicine Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr/Sarah Abdel Kader El Makeep**, Lecturer of Internal Medicine Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Mohammed Ali Awaden**, Lecturer of Internal Medicine Misr University for Science and Technology, for his kindness, supervision and cooperation in this work.*

*I am also grateful to **Dr. Marwa Mosaad Shakweer**, Associate Professor of Pathology, Faculty of Medicine – Ain Shams University, for her great efforts and time he had devoted in this work.*

*Helmy Adel Abd El Khalik*

# *List of Contents*

Title	Page No.
List of Tables .....	5
List of Figures .....	8
List of Abbreviations .....	12
Introduction .....	1
Aim of the Work .....	18
Review of Literature	
▪ HCV & HBV .....	19
▪ Liver Cirrhosis and its Complications .....	65
▪ Gastritis .....	102
▪ Farnesoid X Receptor (FXR) and Liver Diseases .....	120
Patients and Methods .....	137
Results .....	153
Discussion .....	169
Summary .....	176
Conclusion .....	178
Recommendations .....	179
References .....	180
Arabic Summary .....	—

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Hepatitis C-related extrahepatic manifestations.....	30
<b>Table (2):</b>	Approved HCV drugs in the European Union in 2016.....	35
<b>Table (3):</b>	Treatment recommendations for HCV-monoinfected or HCV/HIV coinfectd patients with chronic hepatitis C without cirrhosis, including treatment – naïve patients and patients who failed on a treatment based on PegIFN- $\alpha$ and ribavirin (RBV).....	36
<b>Table (4):</b>	Treatment recommendations for HCV-monoinfected or HCV/HIV patients with hepatitis C with compensated (child – Pugh A) cirrhosis, including treatment – naïve patients and patients who failed on a treatment based on PegIFN- $\alpha$ and ribavirin (RBV).....	37
<b>Table (5):</b>	Phases of chronic hepatitis B .....	47
<b>Table (6):</b>	Interpretation of serologic testing.....	53
<b>Table (7):</b>	Approved antiviral therapies in adultes and children.....	64
<b>Table (8):</b>	Clinical features of cirrhosis .....	69
<b>Table (9):</b>	Grades of Hepatic Encephalopathy.....	72
<b>Table (10):</b>	Types of Hepatic Encephalopathy.....	73
<b>Table (11):</b>	Diagnostic Criteria for Hepatorenal Syndrome .....	73
<b>Table (12):</b>	Laboratory tests in cirrhosis.....	78
<b>Table (13):</b>	Laboratory findings in correlation with cause of liver cirrhosis .....	79
<b>Table (14):</b>	Biochemical and histological markers of liver cirrhosis .....	82
<b>Table (15):</b>	Modified Child-Pugh.....	83

## *List of Tables Cont...*

Table No.	Title	Page No.
<b>Table (16):</b>	Antifibrotic drugs .....	84
<b>Table (17):</b>	Indications for liver transplantation .....	86
<b>Table (18):</b>	Contraindication for liver transplantation.....	87
<b>Table (19):</b>	Classification of portal hypertension according to the anatomic site of increased resistance to portal blood flow.....	88
<b>Table (20):</b>	Hemodynamic parameters measured by Doppler ultrasound.....	96
<b>Table (21):</b>	OLGA Staging system for gastritis.....	107
<b>Table (22):</b>	Indications for H Pylori infection .....	109
<b>Table (23):</b>	Treatment of H. pylori.....	111
<b>Table (24):</b>	Comparison among the studied groups regarding Demographic characteristics. ....	154
<b>Table (25):</b>	Comparison among the studied groups regarding CBC.....	155
<b>Table (26):</b>	Comparison among the studied groups regarding renal functions.....	156
<b>Table (27):</b>	Comparison among the studied groups regarding liver functions.....	157
<b>Table (28):</b>	Comparison between studied groups regarding Ultrasonography, endoscopy and clinical scores. ....	158
<b>Table (29):</b>	Comparison between studied groups regarding Histopathological findings.....	159
<b>Table (30):</b>	Comparison between high and low FXR regarding demographic characteristics .....	161
<b>Table (31):</b>	Comparison between high and low FXR regarding laboratory parameters among group-A.....	162
<b>Table (32):</b>	Comparison between high and low FXR regarding laboratory parameters among group-B.....	163

*List of Tables Cont...*

Table No.	Title	Page No.
<b>Table (33):</b>	Comparison between high and low FXR regarding laboratory parameters among group-C.....	164
<b>Table (34):</b>	Comparison between high and low FXR regarding ultrasonography, endoscopy and clinical scores. ....	166
<b>Table (35):</b>	Comparison between high and low FXR regarding histopathological findings.....	167
<b>Table (36):</b>	Diagnostic characteristics of high FXR to differentiate group-B from group-C.....	168

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	The estimated prevalence of anti-HCV in the world in 2010 .....	20
<b>Figure (2):</b>	Natural history of hepatitis C.....	21
<b>Figure (3):</b>	Global HCV prevalence. ....	22
<b>Figure (4):</b>	Proteins encoded by HCV genome .....	25
<b>Figure (5):</b>	The estimated prevalence of HCV infection and distribution of HCV genotypes across the world .....	26
<b>Figure (6):</b>	Geographic distribution of chronic hepatitis B infection.....	39
<b>Figure (7):</b>	The structure of hepatitis B virus.....	43
<b>Figure (8):</b>	Hepatitis B virus replication.....	45
<b>Figure (9):</b>	Sinusoidal events during fibrosing liver injury changes in the subendothelial space of disse and sinusoid as fibrosis develops in response to liver injury include alterations in both cellular responses and extracellular matrix composition .....	67
<b>Figure (10):</b>	Phenotypic features of hepatic stellate cell activation during liver injury and resolution following liver injury .....	68
<b>Figure (11):</b>	The measurement of HVPG in healthy individuals (A) and in patients with portal hypertension due to sinusoidal causes (B) .....	89
<b>Figure (12):</b>	Causes of portal hypertension .....	90
<b>Figure (13):</b>	Porto systemic collateral pathways .....	94
<b>Figure (14):</b>	Schematic of pathways for cirrhosis-induced portal hypertension.....	95
<b>Figure (15):</b>	Para umbilical collaterals .....	98
<b>Figure (16):</b>	Total portal vein flow reversal. Longitudinal view of the main portal vein and right portal vein (PV) shows retrograde flow (arrow) in both vessels .....	98



## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (17):</b>	Endoscopy showing oesophageal varices.....	101
<b>Figure (18):</b>	<i>H. pylori</i> induced active corporal gastritis gastric gland showing pititis with luminal curvilinear <i>H. pylori</i> (a: H&E; b: Giemsa, 40X).....	103
<b>Figure (19):</b>	Different sites of the stomach showing <i>H. pylori</i> infection status .....	119
<b>Figure (20):</b>	Alcohol consumption is ubiquitous in the United States and worldwide.....	121
<b>Figure (21):</b>	Bile acids (BAs) are amphipathic molecules synthesized from cholesterol in the liver .....	124
<b>Figure (22):</b>	FXR and inflammatory bowel disease .....	127
<b>Figure (23):</b>	The potential of FXR agonists for the treatment of NASH .....	130
<b>Figure (24):</b>	Role of FXR carbohydrate metabolism and lipid metabolism.....	130
<b>Figure (25):</b>	OCA – induced FXR activation.....	136
<b>Figure (26):</b>	Immunohistochemical expression of FXR in normal gastric tissue used as positive control showing strong nuclear and non specific cytoplasmic staining of gastric foveoli and mucosal glands (FXR,IHCX100) .....	146
<b>Figure (27):</b>	Higher magnification of the previous field showing strong nuclear and non specific cytoplasmic staining of gastric foveoli and mucosal glands (FXR,IHCX200).....	146
<b>Figure (28):</b>	A case of chronic active gastritis (group 1) showing moderate activity with prominent infiltration of gastric pits by neutrophils (pititis) (H&E stain X400).....	147

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (29):</b>	A case of Hpylori associated chronic active gastritis (group 1) showing dense Hpylori infection in gastric pits (3+) (H&E, oil immersion X1000).....	147
<b>Figure (30):</b>	A case of chronic active gastritis showing low FXR expression with focal moderate nuclear staining and non specific moderate cytoplasmic staining in gastric foveolae (FXR,IHC X200).....	148
<b>Figure (31):</b>	A case of chronic active gastritis (group 1) showing low FXR expression with predominant negative nuclear staining and non specific mild cytoplasmic staining in gastric foveolae (FXR,IHC X200) .....	148
<b>Figure (32):</b>	A case of chronic HCV (group 2) not associated with gastritis with unremarkable histopathological changes (H&E 200).....	149
<b>Figure (33):</b>	Immunohistochemical expression of FXR of the same case showing strong nuclear staining of gastric foveolae and pits(FXR, IHC X200).....	149
<b>Figure (34):</b>	A case of chronic HCV (group 2) associated with chronic active gastritis showing moderate activity (neutrophilic infiltrate; pititis) and moderate chronicity (lymphoplasmacytic infiltrate in lamina propria) (H&EX400).....	150
<b>Figure (35):</b>	Immunohistochemical expression of FXR of the same case showing high expression with strong diffuse nuclear and non specific cytoplasmic staining of gastric foveolae and pits (FXR,IHCX100) .....	150

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (36):</b>	Gastric biopsy of a case of HCV associated with portal hypertension (group 3) showing vascular ectasia (congestive gastropathy) and moderate chronic active gastritis in form of lymphoplasmacytic infiltrate in lamina propria (H&EX200) .....	151
<b>Figure (37):</b>	Gastric biopsy of a case of HCV associated with portal hypertension (group 3) with vascular ectasia in superficial mucosal blood vessels (arrows) (H&EX200) .....	151
<b>Figure (38):</b>	Immunohistochemical expression of FXR in gastric biopsy of group 3 showing diffuse negative nuclear immunostaining of gastric glands (FXR,IHCX200).....	152
<b>Figure (39):</b>	Immunohistochemical expression of FXR in gastric biopsy of group 3 showing diffuse negative nuclear immunostaining of gastric glands (FXR,IHCX400).....	152
<b>Figure (40):</b>	Histopathological findings among the studied groups .....	160
<b>Figure (41):</b>	Comparison between high and low FXR regarding PC.....	165
<b>Figure (42):</b>	Comparison between high and low FXR regarding INR. ....	165

## *List of Abbreviations*

Abb.	Full term
AFP .....	Alpha-fetoprotein
ALD.....	Alcoholic liver disease
ALT .....	Alanine aminotransferase
anti-HAV .....	Antibody to hepatitis A virus
anti-HCV .....	Antibody to hepatitis C virus
anti-HIV .....	Antibody to human immunodeficiency virus
AST .....	Aminotransferase
BACS .....	Bile acid-CoA synthetase
Bas .....	Bile acids
BCP.....	Basal core promoter
BMI.....	Body mass index
BSEP.....	Bile salt export pump
CAP .....	Controlled attenuation parameter
CBC.....	Complete blood cell count
CBP .....	Combined biomarker panel
CccDNA .....	Covalently closed circular DNA
CD .....	Crohn's disease
CK-18.....	Cytokeratin 18
CSR .....	Communicable Diseases Surveillance and Response
CT .....	Computed tomography
DBD .....	DNA binding domain
DCs.....	Dendritic cells
dupA .....	Duodenal ulcer-promoting gene
EIA.....	Enzyme-immunoassays
ELF .....	Enhanced Liver fibrosis panel
ETV .....	Entecavir
FDA.....	Food and Drug Administration
FGF .....	Fibroblast growth factor
FGF-21.....	Fibroblast growth factor 21
FXR.....	Farnesoid X receptor

*List of Abbreviations Cont...*

Abb.	Full term
gGT .....	$\gamma$ -glutamyltranspeptidase
GI .....	Gastrointestinal
HBeAg.....	Hepatitis B e antigen
HBIG.....	HB immunoglobulin
HBsAg.....	Hepatitis B surface antigen
HBV .....	Hepatitis B virus
HCC .....	Hepatocellular Carcinoma
HCV .....	Hepatitis C virus
HFD .....	High-fat diet
HIV .....	Human immunodeficiency virus
HNF4 $\alpha$ .....	Hepatic nuclear factor 4 $\alpha$
HUs .....	Hounsfield units
ICP .....	Increased intracranial pressure
ICU .....	Intensive care unit
IFN.....	Interferon
IP.....	In-phase
ITT .....	Intention-to-treat
KC .....	Keratinocyte-derived chemokine
kPa .....	Kilopascal
LBD.....	Ligand binding domain
LDLR .....	Low-density lipoprotein receptor
LRH-1 .....	Liver receptor homolog-1
MCD.....	Methionine and choline-deficient
MELD .....	Model for End-Stage Liver Disease
MRI .....	Magnetic resonance imaging
MRP2 .....	Multidrug resistance-associated protein 2
MRP4 .....	Multidrug resistance protein 4
MRS .....	Magnetic resonance spectroscopy
MRS .....	Magnetic resonance spectroscopy

## *List of Abbreviations Cont...*

Abb.	Full term
NAFL .....	Nonalcoholic fatty liver
NAFLD .....	Non alcoholic fatty liver
NAS.....	NAFILD activity score
NAS.....	NAFLD activity score
NASH.....	Non alcoholic fatty liver and steatohepatitis
NBI .....	Narrow band imaging
NIH.....	National Institutes of Health
OCA .....	Obeticholic acid
OLGA.....	Operative Link on Gastritis Assessment
OMP .....	Outer membrane protein
OP .....	Out-of-phase
ORF.....	Open reading frame
OST $\alpha/\beta$ .....	Organic solute transporter $\alpha/\beta$
PAI.....	Pathogenicity island
PBC.....	Primary biliary cirrhosis
PEG-IFN .....	Pegylated interferon
RBV.....	Ribavirin
RNA .....	Ribonucleic acid
SHP.....	Small heterodimer partner
STD.....	Sexually transmitted disease
T4SS .....	Type IV secretion system
TDF.....	Tenofovir disoproxil fumarate
TZD.....	Thiazolidinediones
UC .....	Ulcerative colitis
UDCA .....	Ursodeoxycholic acid
UDCA .....	Ursodeoxycholic acid
UTRs.....	Untranslated regions
VacA.....	Vacuolating cytotoxin
VCTE .....	Vibration-controlled transient elastography

# **WHO WORLD HEALTH ORGANIZATION**